ZMPSTE24 and Insulin resistance: Treating HGPS patients with the farnesyltransferase inhibitor Lonafarnib improved weight gain [18] and reduced prevalence of stroke [75], but did not affect other parameters, including insulin resistance (seen in 35% of patients; [18]).